All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Stem cell-derived pancreatic islet cell progenitors
Therapeutic Area: Endocrinology Product Name: PEC-Encap
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: ViaCyte Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 05, 2020
Details:
Parties have signed an agreement covering the next phase of their ongoing collaboration focused on the development of ViaCyte's Encaptra® Cell Delivery System enabled by proprietary Gore advanced material technologies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ent001
Therapeutic Area: Endocrinology Product Name: Ent001
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Sofinnova Partners
Deal Size: $33.1 million Upfront Cash: Undisclosed
Deal Type: Series A Financing July 28, 2020
Details:
Proceeds to be used for clinical proof-of-concept for lead product Ent001 (IGFBP3/TMEM219 inhibitor) for type 1 diabetes, gastrointestinal diseases and progress pipeline assets.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Frazier Healthcare Partners
Deal Size: $34.6 million Upfront Cash: Undisclosed
Deal Type: Series A Financing July 27, 2020
Details:
Proceeds of the financing will support MBX as it advances its preclinical pipeline of peptide therapeutic candidates directed at clinically validated molecular targets.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GPX-002
Therapeutic Area: Endocrinology Product Name: GPX-002
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $2.5 million Upfront Cash: Undisclosed
Deal Type: Funding July 21, 2020
Details:
The grant will assist Dr. Gittes’s development for his research project titled, “Alpha Cell Conversion to Beta Cells in Non-human Primates” and will build upon his accumulating groundbreaking gene therapy work toward finding a cure for diabetes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): siRNA
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2020
Details:
The company has identified a promising modified delivery vector ready for possible pre-clinical experiments based on stable siRNA (small interfering ribonucleic acid) incorporation within the delivery vehicle.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PTH(1-34)
Therapeutic Area: Endocrinology Product Name: PTH(1-34)
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding July 07, 2020
Details:
The grant was conferred for the development of a long acting parathyroid hormone – PTH(1-34) – that can be administered once-weekly for treatment of hypo-parathyroidism.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Peptide
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2020
Details:
The application is directed to new peptides from the company’s two peptide classes, and their use in the treatment of diabetes and its complications.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GL0034
Therapeutic Area: Endocrinology Product Name: GL0034
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2020
Details:
Pre-clinical performance of GL0034 was assessed in a highly relevant type 2 diabetes db/db mouse model. The NCE demonstrated significant outcomes on various diabetic parameters and a marked and meaningful reduction in triglyceride levels.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AZP-3601
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2020
Details:
Amolyt Pharma is developing AZP-3601, a parathyroid hormone analog specifically designed for the treatment of hypoparathyroidism, as well as AZP-3404, a peptide with a new and unique mechanism of action on fat and glucose metabolism.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
